Vietnam unlikely to meet 80% drug production target by 2030
Local manufacturers remain concentrated in lower-value activities.
Vietnam is unlikely to produce enough pharmaceuticals domestically for 80% of local demand by 2030, due to heavy reliance on imported medicines and limited research and development (R&D) capabilities.
According to a BMI report, the country’s pharmaceutical imports are forecast to increase to $4.3b (VND118t) by 2030 from $3.2b (VND81.6t) in 2025.
The government approved a decision in October, outlining a pharmaceutical industry development strategy through 2030, with a longer-term vision for 2045.
It aims to strengthen pharmaceutical security by expanding active pharmaceutical ingredient (API) production, technology transfer, R&D investment and international collaboration.
By 2030, Vietnam aims to meet around 20% of domestic pharmaceutical raw material demand, establish at least two internationally accredited pharmaceutical R&D centres and achieve annual export growth of at least 10% for high-value pharmaceutical products.
Despite this, BMI said translating these targets into a competitive domestic industry would remain challenging.
The report noted that local manufacturers remain concentrated in lower-value activities such as generic drug formulation and packaging, whilst capabilities in complex formulations, biologics and innovative medicines remain limited.
Low R&D spending is another constraint as the country allocates just 0.4% of gross domestic product (GDP) to R&D, compared with 1.8% in Singapore, 1.2% in Thailand and 1.0% in Malaysia.
BMI said Vietnam's localisation agenda could increase pressure on multinational pharmaceutical companies to expand local investments, transfer technology and establish partnerships with domestic manufacturers.
However, attracting these investments will remain difficult amid workforce capability gaps, intellectual property concerns and high regulatory compliance costs.
The country's stronger economic outlook is expected to support pharmaceutical development spending. BMI raised its GDP growth forecast to 8.7% for 2026 and 7.9% for 2027, from previous estimates of 7.4% and 7.2%, respectively.
BMI expects pharmaceutical localisation to advance gradually, with self-sufficiency remaining a longer-term objective rather than an achievable outcome by 2030.